ALK and anaplastic large cell lymphoma: In a similar manner, we have shown that activation of signalling via the IL10R bypasses NPM-ALK to activate STAT3 in ALCL mediating resistance to crizotinib, alectinib, brigatinib and lorlatinib [142].